Abstract
The androgen receptor (AR) is the most important therapeutic target for metastatic prostate cancer. Though clinical responses to AR inhibition are nearly universal, so is progression, usually accompanied by reactivation of AR signaling. A new small-molecule dual AR degrader/inhibitor shows promise in overcoming resistance and improving clinical outcomes. See related article by Nayak et al., p. 224.